Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00464061
Registration number
NCT00464061
Ethics application status
Date submitted
19/04/2007
Date registered
20/04/2007
Date last updated
26/05/2016
Titles & IDs
Public title
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
Query!
Scientific title
Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study
Query!
Secondary ID [1]
0
0
EudraCT : 2006-004942-18
Query!
Secondary ID [2]
0
0
LTE6673
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SAMS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Sleep Initiation and Maintenance Disorders
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Volinanserin
Treatment: Drugs - Placebo
Experimental: Volinanserin -
Placebo Comparator: Placebo -
Treatment: Drugs: Volinanserin
oral administration
Treatment: Drugs: Placebo
oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Efficacy: change from baseline for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
at 3 months
Query!
Primary outcome [2]
0
0
Efficacy (sub-study): change from baseline for glycemic measure HbA1c
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
at 6 and 12 months
Query!
Secondary outcome [1]
0
0
Efficacy: change from baseline of the pr-WASO
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
at 6 and 12 months
Query!
Secondary outcome [2]
0
0
Efficacy: change from baseline of "General Productivity" domain score of the Functional Outcomes of Sleep Questionnaire
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
at 3 months
Query!
Secondary outcome [3]
0
0
Safety: adverse events and laboratory abnormalities
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
during 12 months of treatment
Query!
Eligibility
Key inclusion criteria
- Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental
Disorders (Fourth Edition) criteria
- Disturbances of sleep maintenance criteria based on participant's information related
to sleep pattern during the preceding month
Sub-study :
- Participants will be included if they have an established medical diagnosis of type II
Diabetes Mellitus, and have been treated either with an oral hypoglycemic agent and/or
insulin for at least three months prior to the Screening Visit (with stable regimen
for at least one month prior to screening)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Females who are lactating or who are pregnant
- Night shift workers, and individuals who nap 3 or more times per week over the
preceding month
- Consumption of xanthine-containing beverages (i.e. tea, coffee, cola) comprising more
than 5 cups/day
- Participation in another trial having received study medication within 1 month before
the screening visit
- Body Mass Index = 33
- Use of over-the-counter medications such as tryptophan, valerian root, kava,
melatonin, St. John's Wort, Alluna or prescription sleep medication
- Use of any substance with psychotropic effects or properties know to affect sleep/wake
- History of primary hypersomnia, narcolepsy, breathing-related sleep disorder,
circadian rhythm sleep disorder, parasomnia, dyssomnia
- Clinically significant, severe or unstable, acute or chronically progressive medical
or surgical disorder
- Positive qualitative urine drug screen (opiates, cocaine, amphetamine…)
The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1847
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Sanofi-Aventis Administrative Office - Macquarie Park
Query!
Recruitment postcode(s) [1]
0
0
- Macquarie Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
New Jersey
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Buenos Aires
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Vienna
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Diegem
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Sao Paulo
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Laval
Query!
Country [7]
0
0
Chile
Query!
State/province [7]
0
0
Santiago
Query!
Country [8]
0
0
Colombia
Query!
State/province [8]
0
0
Santafe de Bogota
Query!
Country [9]
0
0
Czech Republic
Query!
State/province [9]
0
0
Praha
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Hong Kong
Query!
State/province [11]
0
0
Causeway Bay
Query!
Country [12]
0
0
India
Query!
State/province [12]
0
0
Mumbai
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Milano
Query!
Country [14]
0
0
Malaysia
Query!
State/province [14]
0
0
Kuala Lumpur
Query!
Country [15]
0
0
Mexico
Query!
State/province [15]
0
0
Mexico
Query!
Country [16]
0
0
Russian Federation
Query!
State/province [16]
0
0
Moscow
Query!
Country [17]
0
0
Singapore
Query!
State/province [17]
0
0
Singapore
Query!
Country [18]
0
0
South Africa
Query!
State/province [18]
0
0
Midrand
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Barcelona
Query!
Country [20]
0
0
Turkey
Query!
State/province [20]
0
0
Istanbul
Query!
Country [21]
0
0
United Kingdom
Query!
State/province [21]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess efficacy and safety of volinanserin in the population
of patients complaining of sleep maintenance insomnia. The objective of the substudy is to
assess glycemic control in the subgroup of patients with type II diabetes mellitus.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00464061
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ICD CSD
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00464061
Download to PDF